Fussen Pharmaceutical (01652) announced that it is expected that the Group's companies for the year ended December 31, 2023 will...
According to the Zhitong Finance App, Fussen Pharmaceutical (01652) issued an announcement. It is estimated that the Group's expected loss due to company owners for the year ending December 31, 2023 is about RMB 35 million to RMB 43 million, while the loss attributable to company owners for fiscal year 2022 is approximately RMB 34.6 million.
The board of directors believes that the continued loss in FY2023 results is mainly due to the Group increasing investment in R&D and laying out future new product pipelines, while the Group expects R&D costs to increase by about RMB 50 million compared to the same period last year (FY2022: approximately RMB 15.2 million).